Fabien Vincent
Pfizer (United States)(US)
Publications by Year
Research Areas
Cytokine Signaling Pathways and Interactions, Computational Drug Discovery Methods, Monoclonal and Polyclonal Antibodies Research, Ion Channels and Receptors, Phytochemicals and Antioxidant Activities
Most-Cited Works
- → Opportunities and challenges in phenotypic drug discovery: an industry perspective(2017)923 cited
- → Phenotypic drug discovery: recent successes, lessons learned and new directions(2022)303 cited
- → Identification and characterization of novel TRPV4 modulators(2009)236 cited
- → Developing predictive assays: The phenotypic screening “rule of 3”(2015)199 cited
- → Discovery of a JAK3-Selective Inhibitor: Functional Differentiation of JAK3-Selective Inhibition over pan-JAK or JAK1-Selective Inhibition(2016)191 cited
- → Dual Inhibition of TYK2 and JAK1 for the Treatment of Autoimmune Diseases: Discovery of (( S )-2,2-Difluorocyclopropyl)((1 R ,5 S )-3-(2-((1-methyl-1 H -pyrazol-4-yl)amino)pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl)methanone (PF-06700841)(2018)170 cited
- → Design of a Janus Kinase 3 (JAK3) Specific Inhibitor 1-((2S,5R)-5-((7H-Pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)prop-2-en-1-one (PF-06651600) Allowing for the Interrogation of JAK3 Signaling in Humans(2017)160 cited
- → Discovery of PF-06928215 as a high affinity inhibitor of cGAS enabled by a novel fluorescence polarization assay(2017)159 cited
- → TRPV4 Agonists and Antagonists(2011)155 cited
- → Discovery of Clinical Candidate 1-{[(2 S ,3 S ,4 S )-3-Ethyl-4-fluoro-5-oxopyrrolidin-2-yl]methoxy}-7-methoxyisoquinoline-6-carboxamide (PF-06650833), a Potent, Selective Inhibitor of Interleukin-1 Receptor Associated Kinase 4 (IRAK4), by Fragment-Based Drug Design(2017)139 cited